Pyrrolidine Derivatives Selective DPP-IV Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

DPP-IV inhibitors for Type II diabetes often exhibit inhibitory activity against DPP-VIII, leading to side effects such as toxicity and thrombocytopenia, necessitating the development of compounds with minimal or no activity against DPP-VIII.

Innovation Solution

Pyrrolidine compounds of specific formulae that inhibit DPP-IV while showing low inhibitory activity against DPP-VIII, thereby reducing side effects and enhancing insulin secretion and glucose control.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If DPP-IV inhibitors are developed for Type II diabetes treatment, then insulin secretion is enhanced and blood glucose levels are reduced, but inhibitory activity against DPP-VIII causes toxicity and thrombocytopenia

Engineering Contradiction:

Improvediabetes treatment efficacyVSAvoidtoxicity and thrombocytopenia

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing specific molecular regions in the pyrrolidine compound structure that selectively interact with DPP-IV active site residues while avoiding DPP-VIII binding. The compounds feature specific substituent patterns at defined positions that create steric and electronic properties tailored for DPP-IV selectivity, thereby achieving differential inhibition of the two enzymes based on subtle structural differences in their active sites.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and stereochemistry of the pyrrolidine core structure. By optimizing these parameters, the compounds achieve enhanced binding affinity for DPP-IV while maintaining reduced affinity for DPP-VIII, thus improving therapeutic index through precise molecular parameter control.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If broad-spectrum peptidase inhibition is achieved, then multiple peptidases including DPP-IV are inhibited, but selectivity against DPP-VIII is lost leading to side effects

Engineering Contradiction:

Improvepeptidase inhibition spectrumVSAvoidside effects from DPP-VIII inhibition

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies segmentation by dividing the peptidase inhibition function into selective segments - the pyrrolidine compound structure contains specific functional groups and spatial arrangements that segment the inhibition profile to target DPP-IV while excluding DPP-VIII. This segmented approach allows independent optimization of DPP-IV binding without compromising selectivity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses the pyrrolidine compound as an intermediary molecule that mediates selective enzyme inhibition. The compound's specific structural features act as intermediaries that bridge the gap between the desired therapeutic effect (DPP-IV inhibition) and the need to avoid harmful effects (DPP-VIII inhibition), enabling selective interaction through molecular recognition.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP2252582B1Pyrrolidine derivatives

Publication Date: 2014.07.23 NATIONAL HEALTH RESEARCH INSTITUTE

AI summary

Pyrrolidine compounds described herein and methods for using them to inhibit dipeptidyl peptidase IV and treat Type II diabetes.